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Abstract  23 
Circadian rhythms regulate a vast array of physiological and cellular processes, as well 24 
as the hormonal milieu, to keep our cells synchronised to the light-dark cycle. Epidemiologic 25 
studies have implicated circadian disruption in the development of breast and other cancers, 26 
and numerous clock genes are dysregulated in human tumours. Here we review the evidence 27 
that circadian rhythms, when altered at the molecular level, influence cancer growth. We also 28 
note some common pitfalls in circadian-cancer research and how they might be avoided to 29 
maximise comparable results and minimise misleading data. 30 
Studies of circadian gene mutant mice, and human cancer models in vitro and in vivo, 31 
demonstrate that clock genes can impact tumourigenesis. Clock genes influence important 32 
cancer related pathways, ranging from p53-mediated apoptosis to cell cycle progression. 33 
Confusingly, clock dysfunction can be both pro- or anti- tumourigenic in a model and cell type 34 
specific manner. Due to this duality, there is no canonical mechanism for clock interaction with 35 
tumourigenic pathways. 36 
 To understand the role of the circadian clock in patients’ tumours requires analysis of 37 
the molecular clock status compared to healthy tissue. Novel mathematical approaches are 38 
under development, but this remains largely aspirational, and is hampered by a lack of temporal 39 
information in publicly available datasets.  40 
Current evidence broadly supports the notion that the circadian clock is important for 41 
cancer biology. More work is necessary to develop an overarching model of this connection. 42 
Future studies would do well to analyse the clock network in addition to alterations in single 43 
clock genes. 44 
 45 
Alternative Gene Abbreviations: BMAL1 (ARNTL, MOP3), DEC1/2 46 
(BHLHE40/BHLHE41), REV-ERBα/β (NR1D1/NR1D2), CK1δ/ε (CSNK1D, CSNK1E), 47 
NFIL3 (E4BP4)  48 
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Introduction 49 
In 1729, French astronomer Jean-Jaques d’Ortous de Mairan observed the Mimosa 50 
pudica plant opening and closing its leaves in accordance with the geophysical day, even when 51 
deprived of a light source (de Mairan, 1729). In the centuries since, oscillations that coordinate 52 
normal physiology with the 24-hour light/dark cycle have been discovered across the kingdoms 53 
of life (Rosbash, 2009). Disrupted circadian rhythms contribute to many human diseases 54 
including diabetes, obesity and depression. An epidemiological link between circadian rhythms 55 
and cancer was established as early as 1996, and multiple papers on this topic have been 56 
subsequently published (Tynes et al., 1996). The WHO classifies circadian disruption as a 57 
probable human carcinogen (IARC, 2019), though there is debate as to the validity or strength 58 
of this association (Zhang and Papantoniou, 2019, Rivera et al., 2020, Dun et al., 2020, 59 
Wegrzyn et al., 2017).  60 
Unsurprisingly, circadian influence over the endocrine system has been implicated in 61 
this proposed cancer-circadian link. In 1987, Stevens suggested that melatonin suppression 62 
from light at night may play a role in breast cancer biology (Stevens, 1987).  This ‘melatonin 63 
hypothesis’ is out-of-vogue currently owing to contradictory data, these discrepancies and 64 
potential explanations for them are well reviewed by Hunter and Figueiro (Hunter and Figueiro, 65 
2017). There is established circadian variation in many cancer relevant hormones including 66 
melatonin, sex hormones, thyroid hormones and corticosteroids (Prasai et al., 2011). In fact, 67 
the link between hormones, circadian rhythms, and cancer is not one way. Pheochromocytomas 68 
have been observed disrupting circadian rhythms via aberrant hormone release (Tabebi et al., 69 
2018). 70 
At the cellular level, animal models deficient for one or more core circadian genes are 71 
cancer prone (Fu et al., 2002). Cancers are known for aberrant gene expression and therefore, 72 
it is possible that the circadian system is dysregulated within tumours, irrespective of the 73 
rhythm of the animal as a whole. Indeed, an association between cancer severity and circadian 74 
status of the tumour has been documented, and escape from circadian regulation is suggested 75 
to be an emerging hallmark of cancer (Papagiannakopoulos et al., 2016, El-Athman and 76 
Relógio, 2018). Despite this, our understanding of the role of the circadian system and the 77 
influence of specific circadian genes, in tumourigenesis is still developing. 78 
 79 
Page 4 of 30 
 80 
Molecular Clockwork 81 
In most mammals, light is a strong ‘Zeitgeber’, i.e., an external cue that can entrain 82 
circadian rhythms (Duffy and Czeisler, 2009). Light triggers a signal which is transmitted to 83 
the suprachiasmatic nuclei (SCN), an area of the ventral hypothalamus referred to as the 84 
‘central pacemaker’ (Gooley et al., 2001, Hattar et al., 2002). These signals reset the clock in 85 
these neurons by activating light inducible elements in core clock gene promoters (Astiz et al., 86 
2019). The SCN then goes on to synchronise peripheral clocks in cells throughout the body. 87 
Notably, melatonin and glucocorticoid secretion are under SCN regulation and are thought to 88 
have key roles in synchronising peripheral clocks. Glucocorticoids are such strong circadian 89 
synchronisers that they are often use to synchronise cells in vitro for circadian experiments 90 
(Balsalobre et al., 2000, Prasai et al., 2011).  91 
The ultimate units of circadian timekeeping are cell-autonomous 92 
transcriptional/translational/post-translational feedback loops (Fig 1). In the core circadian 93 
loop, the circadian locomotor output cycles kaput (CLOCK) protein forms a heterodimer with 94 
brain and muscle ARNT-like protein 1 (BMAL1). At cycle start, this CLOCK/BMAL1 95 
heterodimer can bind to E-box promoter elements (CANNTG) and promote transcription. 96 
Amongst those genes activated in this way are the period (PER1, PER2 & PER3) and 97 
cryptochrome (CRY1 & CRY2) genes. PER and CRY proteins then accumulate in the cytoplasm 98 
and eventually multimerise forming a ~1 megadalton complex along with Casein Kinase 1 δ 99 
and ε  (CK1δ/CK1ε) and Rab5-activating protein 6 (GAPVD1) (Aryal et al., 2017, Brown et 100 
al., 2005).  101 
In the cytoplasm, post-translational modifications fine tune the system. PER2 is post-102 
translationally regulated via a phosphoswitch mechanism (Zhou et al., 2015). CK1 can 103 
phosphorylate two distinct regions of PER2. Phosphorylation on the FASP (Familial Advanced 104 
Sleep Phase) site leads to PER2 stabilisation, whereas phosphorylation of the degron leads to 105 
degradation via β-TrCP. The ‘decision making’ region appears to be a loop of CK1, the 106 
conformation of which can influence site specificity (Philpott et al., 2020). If PER2 is not 107 
degraded it can be translocated into the nucleus along with CRY proteins and CK1.  108 
In the nucleus, PERs and CRYs repress activity of the CLOCK/BMAL1 heterodimer 109 
by preventing its transcriptional activity or dissociating the complex from DNA (Ye et al., 110 
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2014). Therefore, PERs and CRYs inhibit their own transcription and the transcription of the 111 
numerous genes controlled by CLOCK/BMAL1, which closes the loop. It is worth noting that 112 
CLOCK/BMAL1 is not the only activating complex that can bind to E-boxes. NPAS2 can 113 
substitute for CLOCK at least in some cells (DeBruyne et al., 2007). Moreover, for example, 114 
MYC is also capable of binding to E-boxes in direct competition to the CLOCK/BMAL1 115 
complex and, therefore, MYC can dampen or stop the clock (Altman et al., 2015). 116 
A secondary loop adds to the stability and complexity of the system. The REV-ERBα 117 
and REV-ERBβ promoters contain an E-box, and are transcriptionally activated by the 118 
CLOCK/BMAL1 heterodimer. REV-ERBα and REV-ERBβ compete with retinoic acid-related 119 
orphan receptors (RORα, RORβ & RORγ) for ROR binding sites in the BMAL1 promoter. 120 
RORs activate BMAL1 transcription and REV-ERBs repress it. These primary and secondary 121 
feedback loops constitute the canonical circadian system and have analogues across a variety 122 
of species (Brown et al., 2012). In mammals, however, there are a number of sub-loops which 123 
interlock with either the primary or secondary core loop, proteins involved in these include 124 
DBP, DEC1 and DEC2 (Takahashi, 2016, Nakashima et al., 2008). 125 
Manipulation of key components of these interlocking feedback loops has dramatic 126 
effects on the clock. This is well studied in circadian gene knockout and mutation models in 127 
Drosophila and mice. These modifications to the clock elements range from absolute 128 
arrhythmicity to changes in circadian period, as measured by activity monitoring in whole 129 
animals (Bunger et al., 2000, Lee et al., 2004). Notably, BMAL1 knockout mice are completely 130 
arrhythmic in their behaviour, with nocturnal activity replaced by more random patterns of 131 
activity irrespective of time of day (Bunger et al., 2000). 132 
Clocks in Tumourigenesis 133 
 This intricate system, and disruptions therein, can have profound effects on human 134 
health (Roenneberg and Merrow, 2016). Circadian rhythms influence homeostasis and regulate 135 
a variety of integral hormones including insulin, glucagon, oestrogen and progesterone, as well 136 
as controlling a host of other processes ranging from immunity to metabolism (Petrenko and 137 
Dibner, 2017, Rahman et al., 2019). It is, therefore, unsurprising that circadian biology has 138 
been implicated in a variety of prevalent conditions, including metabolic syndromes, obesity 139 
and cardiovascular disease. This review focuses on the interplay between circadian rhythms 140 
and cancer (Bae et al., 2019, Buurma et al., 2019, Noh, 2018).  141 
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Expression levels of circadian genes, the amplitude of oscillation, and clock output 142 
genes differ between cell types and tissues (Zhang et al., 2014, Mure et al., 2018). Due to this, 143 
there may be distinct pro- or anti-tumourigenic roles for each core clock gene in various tumour 144 
types. A number of studies have attempted to elucidate the roles of each of the clock genes in 145 
various in vitro and in vivo models (Fig 2).  146 
ISSUES WITH MOLECULAR CLOCK RESEARCH IN TUMOURS 147 
Based on animal as well as human studies, more than 20% of all transcripts are clock 148 
regulated and can vary many-fold over the day (Zhang et al., 2014). A lack of timing 149 
information for human tissue samples plagues many of the studies to be discussed. If timing 150 
information is unavailable for bio-samples it is impossible to know if a difference in expression 151 
is due to true differential expression or sampling at different phases of the circadian cycle. 152 
Therefore, care must be taken in interpreting claims of up or downregulated oscillating genes. 153 
Some studies address this by comparing tumour clock gene expression to that of the adjacent 154 
tumour margin (Ye et al., 2018). This approach should still be applied with caution, as tumour 155 
margin cells are not equivalent to healthy cells and it is only assumed that the tumour margin 156 
and the tumour are in phase with each other (Aran et al., 2017).  157 
Even studies in experimental in vitro and in vivo models can suffer from a lack of 158 
information. Overexpression, knockdown or knockout of circadian genes will result in 159 
modified rhythmic gene expression. For example, overexpression of PER2 reduces 160 
transcription of CRY1 & CRY2 and will, therefore, have profound effects on circadian 161 
oscillation (Chen et al., 2009). Therefore, circadian gene manipulations should be proceeded 162 
and succeeded by an assessment of the cell’s overall circadian function. These knock-on effects 163 
may underlie observed phenotypes. Moreover, to compare the consequence of a clock gene 164 
modification across cell lines it would be pertinent to have time-of-sampling information even 165 
for in vitro experiments as this, combined with knowledge of the cells modified rhythmic 166 
behaviour, could shed light on the mechanisms behind cell specific tumourigenic effects of 167 
clock genes. Additionally, clock genes can have pleiotropic effects independent of their core 168 
clock function. For example, CLOCK/BMAL1 can bind to E-box sequences regardless of 169 
whether it is regulated in an oscillatory manner. CLOCK/BMAL1 regulated by the clock, 170 
CLOCK/BMAL1 unregulated by the clock, and complete loss of CLOCK/BMAL1 proteins 171 
each would have different consequences for cell function. These distinctions are likely to apply 172 
to most all circadian proteins. To understand clock gene modifications in the context of the 173 
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overall circadian clock, i.e., functional analysis via reporter assays, multiple timed samples or 174 
the use of one sample combined with the use of a multi-dimensional mathematical model is 175 
required. 176 
BMAL1 177 
In humans, BMAL1 has been associated with a number of cancers including breast, 178 
pancreatic and thyroid tumours, though its role in these endocrine cancers is incongruous. 179 
BMAL1 is often depicted as the centre of the core circadian system, owing to the 180 
BMAL1/CLOCK heterodimer being the canonical positive arm and driver of circadian gene 181 
transcription (Fig 1), and BMAL1 is the only known single gene knockout that is considered to 182 
completely stop the clock (Baggs et al., 2009). Unsurprisingly, this has led it to be amongst the 183 
best studied circadian regulators in regard to tumourigenesis. In breast cancer, reduced BMAL1 184 
is consistently associated with increased risk of metastasis (Ramos et al., 2020). Similarly, 185 
pancreatic cancer cells are reported to have less BMAL1 than non-cancerous controls (Jiang et 186 
al., 2016). However, thyroid carcinoma and a subset of malignant plural mesothelioma (MPM) 187 
had upregulated BMAL1 (Ye et al., 2018, Elshazley et al., 2012). Despite its links to endocrine 188 
related cancers in humans, little evidence thus far has been unearthed linking BMAL1 to 189 
endocrine pathways in tumourigenesis.  190 
In xenograft models BMAL1 appears to be anti-tumourigenic. BMAL1 knockdown 191 
(k/d) in a pancreatic cancer cell line with high endogenous BMAL1 expression (BxPC-3) 192 
increased subcutaneous tumour size and matrix metalloproteases (MMPs) 9 and 2. BMAL1 193 
overexpression in a pancreatic cell line with low endogenous BMAL1 expression (AsPC-1) 194 
showed converse effects (Jiang et al., 2016). This may be a p53 pathway effect as BMAL1 was 195 
shown to be bound to the p53 promoter and overexpression of BMAL1 induced an upregulation 196 
of phospho-p53 whereas BMAL1 k/d reduced it. It is not clear how transcriptional regulation 197 
via BMAL1 could upregulate phospho-p53, but not overall p53 (Jiang et al., 2016). Similarly, 198 
in hepatocellular carcinoma (HCC), BMAL1 also appears to inhibit tumour growth. 199 
Canonically, hepatocyte nuclear factor 4 alpha (HNF4α) is a tumour suppressing transcriptional 200 
repressor. However, a subset of liver tumours expresses an isoform named P2-HNF4α. Both 201 
isoforms of HNF4α can repress BMAL1 transcription, however P2-HNF4α has a much 202 
stronger effect. Forcing P2-HNF4α expressing HCC cells to re-express BMAL1 caused a 203 
reduction in tumour growth subcutaneously in mice and an induction of both p53 and cleaved 204 
caspase 3 (Fekry et al., 2018). 205 
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 BMAL1’s role in tumours appears cell type specific in in vivo models utilising mouse 206 
cancer cells and in vitro models. Murine colon adenocarcinoma (C26) cells with BMAL1 k/d 207 
formed significantly larger tumours than their wildtype (WT) counterparts (Zeng et al., 2010). 208 
In a genetically engineered mouse model of lung adenocarcinoma, tumour specific loss of 209 
BMAL1 increased tumour burden, tumour weight, proliferation and MYC production. Notably, 210 
this effect was absent if performed in a p53 deficient background, adding credence to the 211 
proposed p53-BMAL1 interplay in tumourigenesis (Papagiannakopoulos et al., 2016). 212 
Conversely, in an acute myeloid leukaemia (AML) model in mice it was demonstrated that 213 
BMAL1 k/d cells are depleted in vivo compared to their WT counterparts. This suggests that, 214 
in this instance, BMAL1 confers a survival advantage to the cancer cells (Puram et al., 2016). 215 
Consistent with these findings, HCT116 (human colorectal carcinoma) cells with BMAL1 k/d 216 
formed significantly smaller tumours when grafted onto zebrafish embryos than HCT116 WT. 217 
This model system is further removed from mammalian biology and it is unclear if this 218 
observation is a result of the cell type or the model. Interestingly, in HCT116 BMAL1 k/d cells, 219 
p53 was shown convincingly to oscillate at the mRNA level despite no oscillation at the 220 
BMAL1 promoter (Basti et al., 2020). Studies in vitro have demonstrated BMAL1 acting as a 221 
suppressor of proliferation in BxPC-3, AsPC-1, HCT116, C26 and U87MG (glioblastoma) cell 222 
lines and in patient derived glioblastoma stem cells, but acting as a proliferation enhancer in 223 
the human MPM cell lines ACC-MESO-1 and NCI-H290 (Jiang et al., 2016, Basti et al., 2020, 224 
Zeng et al., 2010, Gwon et al., 2020, Dong et al., 2019, Elshazley et al., 2012).  225 
BMAL1 is suggested to play a role in multiple endocrine and non-endocrine cancers, 226 
though its role does not seem consistent across various models, even within the same cancer 227 
type. Interestingly, the tumour types where BMAL1 is suggested to be pro-tumourigenic, 228 
thyroid carcinoma, mesothelioma and AML are cancer types with low incidence of p53 229 
mutations in humans with ~1%, 15% and 5%, respectively (Donehower et al., 2019). As p53 230 
is prevalent in downstream analysis of BMAL1 k/d effects it is plausible that some p53 231 
mutations in the tumour may influence tumourigenic effects of BMAL1. Discoveries such as 232 
p53 oscillation upon BMAL1 k/d in HCT116 hint at a link to rhythmicity. MMP9 has also been 233 
reported to be suppressed by BMAL1 in glioblastoma, pancreatic and breast cancer suggesting 234 
that BMAL1 may be tied to metastatic and angiogenic potential (Gwon et al., 2020, Jiang et 235 
al., 2016, Wang et al., 2019). It would also be pertinent to have better models in these studies 236 
to more effectively demonstrate clinical relevance. Orthotopic xenografts are largely absent in 237 
BMAL1 manipulation studies and should be considered for their greater clinical relevance in 238 
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BMAL1 and other clock gene studies. Alternatively, as the clock is tied to inflammation and 239 
immunity, the use of humanised mouse models or simply immunocompetent mouse models 240 
may unearth new pathways by which abrogation of the molecular clock impacts tumourigenesis 241 
(Comas et al., 2017). 242 
CLOCK 243 
In humans, CLOCK has been linked to breast cancer and oestrogen signalling (Rossetti 244 
et al., 2012, Xiao et al., 2014). Though it is as yet unclear if there are links between CLOCK 245 
and other tumour relevant hormones. CLOCK, together with its binding partner BMAL1, is a 246 
transcriptional activator. CLOCK is not completely indispensable for circadian function, 247 
though CLOCK has other unique functions such as acting as an acetyltransferase (Doi et al., 248 
2006).  Cadenas et al. (2014) found an association between clock genes and tumours in humans, 249 
combining 766 microarray transcriptomes from several cohorts of breast tumour patients. 250 
Prolonged metastasis free survival was associated with higher expression of a number of 251 
circadian genes, including CLOCK (Cadenas et al., 2014). Fittingly, the six most frequent 252 
single nucleotide polymorphisms (SNPs) that occur in CLOCK are associated with significant 253 
changes in breast cancer risk (Hoffman et al., 2010).  Furthermore, in higher grade gliomas and 254 
ERα-positive breast tumours CLOCK have been reported to be upregulated (Chen et al., 2013, 255 
Xiao et al., 2014).  256 
In vitro and in vivo models show CLOCK as a tumour enhancer. Though it is 257 
significantly less well studied than BMAL1. In a murine AML model cells lacking CLOCK 258 
were depleted compared to WT, much like BMAL1 k/d, and both knockdowns prevented cell 259 
cycle progression (Puram et al., 2016). Similarly, in a subcutaneous flank model of human 260 
colon cancer SW480 cells endogenously expressing low levels of CLOCK, CLOCK 261 
overexpression led to larger tumours after two weeks. Mechanistic interrogation found that 262 
overexpressing CLOCK caused a decrease in apoptosis related proteins BAX and BID and an 263 
increase in p-AKT (Wang et al., 2015b). CLOCK k/d cells also had reduced metastatic potential 264 
in mice and reduced expression of HIF1α, ARNT and VEGF, all known to be key players in 265 
angiogenesis (Wang et al., 2017). In vitro, SW620 cells endogenously expressing high levels 266 
of CLOCK showed decreased proliferation and decreased cell migration after CLOCK k/d, 267 
while CLOCK overexpression in an endogenously low expressing cell line, SW480, resulted 268 
in the opposite effect (Wang et al., 2015b, Wang et al., 2017). CLOCK k/d in U87MG cells 269 
(human glioblastoma) increased apoptosis, along with decreased MYC and CCNB1 (Cyclin 270 
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B1) (Wang et al., 2016). It is at present unclear if the apoptosis mechanism here is the same as 271 
seen in Wang et al. (2015b).  Fittingly, CLOCK k/d has also been demonstrated to reduce 272 
viability in glioblastoma stem cells and induce cleaved caspase 3 (Dong et al., 2019). In 273 
addition to apoptosis and angiogenic related pathways, CLOCK may be integrated closely with 274 
oestrogen (E2) and oestrogen receptor α (ERα) signalling in cancer. In ERα positive breast 275 
cancer cell lines, E2 has been demonstrated to upregulate CLOCK protein and mRNA by 276 
increasing ERα binding to the CLOCK promoter. A CLOCK k/d in these cells reduced 277 
proliferation (Xiao et al., 2014). 278 
The two pathways suggested to give rise to a CLOCK mediated effect on 279 
tumourigenesis are apoptosis and oestrogen signalling. Oestrogen signalling is an attractive 280 
avenue as it has been previously demonstrated that BMAL1 k/d can modify ER signalling and 281 
lead to aberrant breast acinar morphogenesis (Rossetti et al., 2012). It may be pertinent to 282 
investigate if other circadian genes have similar links to oestrogen. Apoptosis-related proteins 283 
have been implicated in this system in multiple studies, therefore it would be useful for future 284 
studies to probe for those proteins that have been implicated before. This would demonstrate if 285 
apoptosis instigated by CLOCK k/d is via the same mechanism in all cell types. Additionally, 286 
some caution must be taken in assuming that CLOCK acts as a tumorigenic enhancer in all 287 
cancers. It is conceivable that its effects are just as cell-type specific as those of its 288 
heterodimeric partner and the research is simply sparser. Notably, in human patients, an anti-289 
tumourigenic role for CLOCK was suggested that is not seen in xenograft models. NPAS2 is a 290 
paralogue of CLOCK that can compensate somewhat for CLOCK loss in the brain, moreover 291 
some evidence suggests that it may also be able to do this in the periphery (DeBruyne et al., 292 
2007, Landgraf et al., 2016). In future it would be interesting for studies to take this into account 293 
and perform double knockdowns.  294 
PERIOD GENES 295 
Of all clock genes, the PER proteins have perhaps the most variable effects on 296 
tumourigenesis, with evidence for a tumour suppressive role and a tumour enhancing role in 297 
both human data and in experimental models. PER1 and PER2 are core components of the 298 
negative arm of the circadian clock as they suppress the function of the CLOCK/BMAL1 299 
heterodimer. PER2 specifically is a very well researched clock protein with a complex 300 
circadian function (Konopka and Benzer, 1971, Philpott et al., 2020). As its expression 301 
oscillates distinctly over the circadian cycle, PER2 is a good rhythm marker. Overexpression 302 
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of PER2 can stop the circadian clock similar to BMAL1 k/o (Chen et al., 2009). Unlike PER1 303 
and PER2, which have similar and well-defined roles in the clock, PER3 remains elusive. Its 304 
role, if any, in cell autonomous clocks appears tissue specific (Pendergast et al., 2012). 305 
However, a number of PER3 polymorphisms have been described with a variety of sleep 306 
phenotypes (Hida et al., 2014).  307 
 Patient sample data thus far suggests a tumour suppressive function for PER1&3, with 308 
PER2’s role being less clear. A large study of datasets in The Cancer Genome Atlas suggested 309 
an overall tumour suppressive role for the PERs, however, PER1,2&3 expression were 310 
associated with pro-tumourigenic inhibition of apoptosis and activation of RAS/MAPK or 311 
receptor tyrosine kinase (RTK) signalling in a sizeable minority of the cancer types analysed 312 
(Ye et al., 2018). Expression of all three PERs differed in 95% of breast tumours relative to 313 
margins, though no statistical analysis was presented for this data. Notably, the PER expression 314 
differed between individuals and between cell populations within tumour slices (Chen et al., 315 
2005). Other groups have found similar results with PER1&2 being under-expressed in breast 316 
tumours and gliomas, and low expression of PER1,2&3 correlating with poorer overall survival 317 
in cases of pancreatic ductal adenocarcinoma (PDA) (Winter et al., 2007, Xia et al., 2010, 318 
Relles et al., 2013). In head and neck squamous cell carcinoma, low expression of both PER1 319 
and PER3 was predictive of poorer 2-year survival. Low PER3 expression was associated with 320 
larger tumour size and increased invasiveness, which are potentially better metrics than 321 
survival as this specific study had a low sample size and high overall 2-year survival (Hsu et 322 
al., 2012). PER1 is reported to be down-regulated in breast tumours relative to healthy controls 323 
and in colorectal cancer low expression was associated with increased metastasis (Gery et al., 324 
2006, Oshima et al., 2011). In gastric cancer PER2 was actually found to be upregulated 325 
compared to paired margin biopsies, complicating its potential role (Hu et al., 2014). Finally, 326 
hetero- or homozygosity for a particular variant of PER3 resulted in 1.7-fold elevated risk of 327 
breast cancer (Zhu et al., 2005).   328 
 Experimentally, PER2 appears anti-tumourigenic in vivo and in vitro. K562, human 329 
chronic myelogenous leukaemia (CML), cells have demonstrated reduced growth capacity in 330 
bone marrow upon PER2 overexpression. Induction of p53 as well as reduced CCNB1 and 331 
MYC were suggested as potential mechanisms (Sun et al., 2010). Similarly, mutation of PER2 332 
increased proliferation of lung cancer cells in mice, this was conserved in a p53 deficient 333 
background (Papagiannakopoulos et al., 2016). In contrast, HCT116 xenografts in zebrafish 334 
embryos showed no change upon PER2 k/d (Basti et al., 2020). Overexpression of PER2 in 335 
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murine Lewis Lung Carcinoma or EMT6 (mouse mammary carcinoma) cells in vitro results in 336 
reduced proliferation and increased apoptosis (Hua et al., 2006). Delivery of PER2 ectopically 337 
to murine lung tumours can reduce their size and growth (Hua et al., 2007). In human pancreatic 338 
cancer cell lines PER2 increases BAX and reduces BCL-X in a dose dependant manner, as well 339 
as in human osteosarcoma where a reduction in PER2 increased phospho-AKT and BCL-2 and 340 
reduced p27 and p21, implicating both cell cycle and apoptosis pathways (Oda et al., 2009, Qin 341 
et al., 2018). Conversely, Basti et al. found, despite the lack of effect in vivo, their PER2 k/d in 342 
HCT116 conferred the highest rate of proliferation in vitro until day 5, similar to PER2’s 343 
tumour suppressive effects in CML and lung cancer cells in vitro (Basti et al., 2020, Sun et al., 344 
2010, Papagiannakopoulos et al., 2016). 345 
Experimental evidence for the role of PER1 and PER3 in tumourigenesis is scarce and 346 
that which is available is purely in vitro. PER1 overexpression is reported to increase DNA 347 
damage induced apoptosis in HCT116 cells, PER1 k/d having the opposite effect (Gery et al., 348 
2006). In PaCa2 (human pancreatic cancer cells) PER1 k/d caused a decrease in proliferation, 349 
PER3 also caused a dip in proliferation but it was found to be statistically insignificant. These 350 
findings in PaCa2 are interesting as TNFα treatment of PaCa2 increases proliferation and 351 
downregulates PER1 and PER3 expression, suggesting PERs may be downstream of this TNFα 352 
effect (Suzuki et al., 2008). PaCa-2 and PANC-1 cell lines both demonstrate increased 353 
apoptosis upon PER1 k/d and display an increase in BAX and cleaved PARP as well as a 354 
decrease in BCL-2 (Sato et al., 2009).  355 
Apoptosis and the cell cycle have both been implicated in the role of the PERs in 356 
tumours.  PER2 is fairly well studied however, PER1 lacks in vivo data and PER3 is generally 357 
understudied. The finding that p53 is dispensable for PER2’s effect on tumourigenesis in 358 
murine lung cancer, contrary to BMAL1, clearly demonstrates that the mechanism of action of 359 
each clock gene in tumourigenesis can be distinct, despite phenotypic similarities 360 
(Papagiannakopoulos et al., 2016). From the data discussed here it seems likely that the anti-361 
tumourigenic effect of PER2 is via a combination of apoptotic and cell cycle effects, though it 362 
remains unclear if the exact same parts of these diverse pathways are involved across multiple 363 
tumour types. PER1 is thought to have a similar role in the circadian system as PER2, however 364 
the minimal mechanistic information in cancer seems to show an opposite effect. PER1 365 
increases BCL-2 and decreases BAX and vice versa for PER2. A study interrogating the 366 
tumourigenic role of both PER1 and PER2 in the same cell line would be ideal.  Sato et al. 367 
suggest PER1’s effect on tumourigenesis may be due to PER1 dysregulation having a wider 368 
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impact on the circadian system as a whole, highlighting the aforementioned importance of 369 
assessing the whole molecular clock in models (Sato et al., 2009).  370 
CRY1 & CRY2 371 
In human cancer the role of the CRYs is very unclear, with studies suggesting they are 372 
tumour suppressive and others suggesting them to be tumour enhancing. The CRY proteins are 373 
important for circadian rhythms across the animal kingdom. In mammals they seem to have 374 
forgone their ancient light sensing ability, but still remain transcriptional repressors which, 375 
along with the PERs form the primary negative arm of the circadian clock (Michael et al., 376 
2017). In humans, CRY2 is associated with prolonged metastasis free survival in breast cancer 377 
and lower CRY2 expression is associated with worsened overall survival in PDA, suggesting a 378 
link between oestrogen related cancer and CRY expression which sadly has not been addressed 379 
in models (Cadenas et al., 2014, Relles et al., 2013). In colorectal cancer, however, CRY1 380 
expression correlates with worse overall survival, and in gastric cancer high CRY1 expression 381 
relative to paired tumour margin is associated with higher cancer stage (Yu et al., 2013, Hu et 382 
al., 2014). 383 
Facilitated by the availability of knock-out mouse models, studies on CRY1- and 384 
CRY2-deficient mice are abundant (van der Horst et al., 1999). Tumour autonomous CRY1 385 
and CRY2 data is much scarcer. CRY1 k/d in HOS and U2OS cell lines (human osteosarcomas) 386 
led to larger tumours in mice (Zhou et al., 2018). This effect was also seen in vitro (Zhou et al., 387 
2018). HCC cells with CRY double knockout in a p53 knockout (k/o) background have been 388 
shown to grow at the same rate as the same cells with just p53 k/o, however the CRY loss 389 
sensitised them to TNFα treatment, suggesting a link to apoptosis and the NF-κB pathway (Lee 390 
and Sancar, 2011). It should be noted that this HCC study was performed in immunodeficient 391 
mice; with a functional immune system these tumours would potentially die due to TNFα 392 
produced by lymphocytes in the tumour microenvironment without the need for endogenous 393 
TNFα.  394 
In vitro, CRY2 appears to be anti-tumourigenic in osteosarcoma but has negligible 395 
effects in breast cancer. CRY2 k/d in HOS cells enhanced cell cycle progression, proliferation 396 
and migration, reducing p53 expression but increasing MYC, CCND1, MMP-2, β-Catenin and 397 
ERK1/2 phosphorylation. The knockdown also modified the circadian landscape in the cells, 398 
increasing CRY1, PER1, PER2, BMAL1, and CLOCK expression (Yu et al., 2018). CRY2 k/d 399 
in MCF7 cells showed no change in cell cycle distribution or apoptosis with or without methyl 400 
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methanesulfonate insult. The only difference observed was a difference in DNA damage 401 
accumulation and an upregulation of p21 and Cyclin D1 (Hoffman et al., 2010).  402 
CRY2’s inhibition of MYC seems important to its role in cancer. An increase in MYC 403 
upon CRY2 k/d is likely due to CRY2’s known role in degrading MYC via cooperative action 404 
with the E3 ubiquitin ligase FBXL3 (Huber et al., 2016). Indeed, in humans, data concerning 405 
PDA, a cancer type inextricably linked to MYC, suggests an increase in CRY2 as beneficial 406 
for patient survival. However, the import of this in tumours is unclear as CRY2 k/o has proved 407 
insufficient for primary cell transformation; expression of MYC combined with CRY2 k/o was 408 
not sufficient to cause colony formation on soft agar (Huber et al., 2016). Therefore, CRY2 409 
may act as an inhibitor of tumour progression but be insufficient to contribute to tumour 410 
initiation. In mouse models CRY’s role seems reversed when p53 is mutated, with the CRYs 411 
acting as tumour enhancers, as loss of CRY acts as a sensitisation factor to TNFα mediated 412 
apoptosis (Ozturk et al., 2009). This suggests a link between CRY2 and p53, which is also 413 
potentially on display in vitro with p21 accumulation upon CRY2 k/d demonstrated by 414 
Hoffman et al. (2010). In human studies it would be interesting to contextualise the role of 415 
CRY in terms of the MYC and p53 status of the tumour. More data is required to fully 416 
understand the role of CRYs in cancers. There is a wealth of data concerning whole animal 417 
knockouts, but they are limited for modelling the clinical situation in human cancers in a 418 
meaningful way, there are no known human conditions which completely remove circadian 419 
proteins in all body cells.	420 
REV-ERBα  & REV-ERBβ 421 
There is evidence to suggest that the REV-ERBs play a role in oestrogen related 422 
tumours in humans, and in in vivo and in vitro cell based studies, although the suggested effect 423 
on tumourigenesis is occasionally inconsistent. The REV-ERBs are part of the secondary 424 
circadian loop as they can bind to elements in the BMAL1 promoter and suppress its 425 
transcription, they have ties to inflammatory pathways and are therefore, attractive targets for 426 
anti-cancer compounds. A number of agonists and antagonists of REV-ERBs have been 427 
developed (Wang et al., 2020). High expression of REV-ERBα is associated with better 428 
prognosis in triple negative breast cancer when the patients were treated with chemotherapy, 429 
leading to better overall and disease-free survival (Na et al., 2019).  430 
REV-ERBs seem to be anti-tumourigenic in most, but not all, cell lines tested thus far.  431 
There are two available REV-ERB agonists which are used in many of the studies discussed 432 
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here, named SR9009 and SR9011. These have proved effective in killing astrocytoma (Becker), 433 
leukaemia (Jurkat), breast (MCF7), colon (HCT116) and melanoma (A375) cell lines in vitro 434 
(Sulli et al., 2018). SR9009 reduced autophagy and increased apoptosis in skin naevi, 435 
glioblastoma  and subcutaneous small cell lung cancer in mice (Sulli et al., 2018, Shen et al., 436 
2020). In HCT116, REV-ERBα k/d is reported to reduce proliferation and micrometastasis 437 
formation in vivo in a zebrafish embryo model. This is in contrast to the in vitro information 438 
from the same study which found enhanced proliferation on REV-ERBα k/d (Basti et al., 2020). 439 
In T98G glioblastoma and HepG2 cells introduction of SR9009 is cytotoxic, but in other 440 
hepatocellular carcinoma cells (Huh7 and HCCLM3) REV-ERBβ appears to increase cell 441 
viability and increase epithelial-mesenchymal transition (Wagner et al., 2019, Tong et al., 442 
2020). Undifferentiated and partially differentiated gastric cancer (BGC-823 & SGC-7901), 443 
demonstrated increased proliferation upon REV-ERBα k/d and the glycolysis and pentose 444 
phosphate pathway were suggested as the potential mechanism (Tao et al., 2019). It must be 445 
noted, however, that these cell lines are known to have misattributed identity, so this data is 446 
potentially more related to HeLa cells than gastric cancer (Ye et al., 2015). 447 
REV-ERBα is tied to breast cancer as it and HER-2 lie on the same amplicon. REV-448 
ERBα k/d reduces viability of HER-2 positive breast cancer cells (BT474), potentially due to 449 
a link between REV-ERBα and fatty acid synthesis (Kourtidis et al., 2010). Conversely, in 450 
other breast cancer cell lines (MDA-MB-231, MCF7, BT474 and MDA-MB-361) SR9011 451 
reduced cell viability. A REV-ERBβ k/d stopped the SR9011 effect therefore, even though 452 
SR9011 acts via both REV-ERBs, in these breast cancer cells SR9011 acted via REV-ERBβ 453 
(Wang et al., 2015a). Both SR9009 and SR9011 were tested on glioblastoma stem cells and 454 
were found to reduce proliferation compared to non-cancerous controls, and they reduced 455 
expression of glioblastoma stem cell markers. SR9011 combined with a CRY stabilisation 456 
agent reduced glioblastoma stem cell viability synergistically, both agents targeting different 457 
molecular feedback loops of the clock (Dong et al., 2019). 458 
REV-ERB research is in an odd position, as there is contradictory data within the same 459 
cancer type in both breast cancer and hepatocellular carcinoma. In a number of breast cancer 460 
cell lines REV-ERBβ appears to be the important REV-ERB, though this may not be true in all 461 
types of breast cancer. From the human data it would be expected that REV-ERB agonists 462 
would be anti-tumourigenic which was true in many, but not all, cell lines studied. The 463 
comparison is not perfect as the human data was specifically in triple negative breast cancer 464 
and involved chemotherapy and the model data was in vitro. An experiment involving REV-465 
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ERB knockdowns and agonists in a triple negative breast cancer line (e.g., MDA-MB-231) in 466 
a clinically relevant in vivo model (e.g., orthotopic) would give greater insight into the role 467 
these proteins play in human tumour biology. As there are already small molecules which show 468 
good efficacy and high specificity at targeting the clock via REV-ERBs, these genes are a 469 
promising route towards circadian based cancer therapies, though it should be noted that the 470 
agonists currently available have been suggested to have anti-proliferative effects independent 471 
of their REV-ERB agonism (Dierickx et al., 2019, Dong et al., 2019). 472 
TIMELESS 473 
TIMELESS was one of the first circadian proteins to be cloned in flies where it is an 474 
integral part to the circadian system (Sehgal et al., 1994). In mammals, a TIMELESS homolog 475 
exists, but its function in mammalian circadian biology is poorly understood, presumably in 476 
part due to the embryonic lethality of TIMELESS k/o (Gotter et al., 2000, Kurien et al., 2019). 477 
In humans, high expression of TIMELESS is associated with shorter metastasis free survival in 478 
breast cancer, meaning its only link to cancer in humans is in oestrogen related cancer (Cadenas 479 
et al., 2014). 480 
This oestrogen related cancer link is also reiterated in vivo. In an orthotopic breast 481 
cancer model TIMELESS k/d was reported to reduce the viability of MCF7 cells (Chi et al., 482 
2017). Similarly, in vitro TIMELESS k/d in MCF7 cells reduces proliferation, and in the 483 
hepatocellular carcinoma cell lines HepG2 and Hep3B TIMELESS k/d causes cell cycle arrest 484 
and slightly increased apoptosis as well as a drop in migration in Hep3B cells (Mao et al., 2013, 485 
Elgohary et al., 2015). Data on TIMELESS is understandably minimal given its unclear role in 486 
the circadian system. The orthotopic in vivo model used by Chi et al. is an improvement over 487 
subcutaneous flank models and could be emulated for breast cancer studies on circadian genes 488 
in future.  489 
DEC1 & DEC2 490 
DEC1 and DEC2 are part of a smaller clock sub-loop which interlocks the primary 491 
circadian feedback loop. DEC1 & DEC2 are E-box containing genes whose corresponding 492 
proteins are known to inhibit CLOCK/BMAL1 heterodimer mediated transcription 493 
(Nakashima et al., 2008). In AML with MLL-AF6 chromosomal rearrangement, DEC2 is 494 
overexpressed. Downregulation of DEC2 increases apoptosis of these cells and reduces their 495 
viability in vivo, though the knockdown does not change the expression of other clock genes 496 
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(Numata et al., 2018). DEC1, however, has been reported to prevent cell cycle progression by 497 
directly binding to, and hence stabilising, Cyclin E (Bi et al., 2015). Overexpression of DEC1 498 
in MCF7 cells reduced tumour size in mouse xenografts significantly (Bi et al., 2015). In MCF7 499 
cells, in vitro, knockdown of DEC2 increased apoptosis, whereas DEC1 did not. Apoptosis 500 
related factors, namely FAS and BAX, were upregulated and MYC expression was decreased 501 
(Wu et al., 2015). 502 
Genes outside of the primary and secondary canonical circadian loops, but which 503 
nonetheless have a role in circadian oscillations, are interesting and much of their function 504 
remains elusive. DEC1 and DEC2 are transcriptional repressors but, as evidenced by the role 505 
of DEC1 in stabilisation of Cyclin E, have roles outside of their transcriptional activity. The 506 
effect that these proteins have on tumourigenesis, as well as their specific role in tumour 507 
rhythms should be studied more closely. 508 
MECHANISM OVERVIEW - P53 509 
The p53 axis is a recurring mechanism linking the clock with cancer biology. This could 510 
prove pivotal as p53 is the single most frequently mutated gene in human cancers. Its ability to 511 
orchestrate cell cycle arrest via p21 and apoptosis via BCL-2 in response to DNA damage 512 
makes removal of p53 function essential for much of malignant growth (Kastenhuber and 513 
Lowe, 2017). As explored in this review, p53 has been linked to BMAL1, PER1, PER2 and 514 
CRY2. The role p53 plays in the cancer biology of each gene is convoluted, for example PER2 515 
status modified p53 abundance in K562 cells, though its tumour suppressive role in lung cancer 516 
was demonstrated to be p53 independent. Additionally, p53 appears to begin cycling when 517 
BMAL1 expression is lost, antithetical to the canonical idea that no BMAL1 means no circadian 518 
oscillation. The ubiquitous role of p53 in cancer makes the cell specific nature of its 519 
involvement confusing, though there are some possible explanations. Firstly, some studies do 520 
not probe for p53 and therefore it may be playing an unseen role in these cells. Secondly, 521 
BMAL1 exerts pro-tumourigenic effects in cell lines with relatively low p53 mutation rates in 522 
patients. Perhaps the natural dependency of the cancer on p53 pathways may give rise to these 523 
cell specific effects.  524 
This mechanism is further complicated by circadian-p53 crosstalk. It has been shown 525 
previously that a reduction of p53 upon PER2 k/d can occur due to PER2 preventing MDM2 526 
mediated ubiquitination of p53 (Gotoh et al., 2014). In turn p53 can block CLOCK/BMAL1 527 
binding to the E-box elements in the PER2 promoter (Miki et al., 2013). If p53 has such strong 528 
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links to PER2 then other clock genes that have an effect on p53 may in fact just be modifying 529 
PER2 expression. Nevertheless. p53 remains an interesting mechanism by which the clock and 530 
cancer may interact.  531 
MECHANISM OVERVIEW - APOPTOSIS 532 
Another potential mechanism by which these genes influence tumourigenesis is via 533 
apoptosis pathways independent of p53. A link between the circadian clock and p53 534 
independent cell death has been previously established, demonstrating a link between NF-κB 535 
signalling and CRY in p53 null cells (Lee and Sancar, 2011). Whilst this is a good indicator of 536 
a circadian-apoptosis link, the data presented here have shown that aberrations in different 537 
clock proteins can lead to differing effects. Across a number of the aforementioned studies, 538 
changes in apoptosis related proteins such as p21 and BAX are fairly common. However, it is 539 
difficult to know if these effects can be traced back to p53. Apoptosis pathways converge 540 
significantly, and the effects of p53 are widespread. Sadly, a number of studies that identify 541 
increased apoptosis as a potential mechanism of tumourigenic modifications by circadian genes 542 
do not probe for p53 specifically, so it is difficult to ascertain which effects are p53 independent 543 
and which are p53 dependant.  544 
MECHANISM OVERVIEW – CELL CYCLE 545 
Cross talk between circadian oscillators and the cell cycle is well established (Farshadi 546 
et al., 2020). Dysregulation of the cell cycle is a key driver of increased proliferative capacity. 547 
In the majority of studies mentioned here there is a change in proliferation upon clock gene 548 
modification. Cell cycle arrest is repeatedly implicated in circadian rhythms and cancer. 549 
Primarily cells were found arrested in G2 (Sun et al., 2010, Elgohary et al., 2015, Wang et al., 550 
2015a). It would be presumptuous to assume that this G2 arrest across various genes and cell 551 
types is caused by the same mechanism, though the consistency is interesting. There are a 552 
number of genes that are important for circadian gene effects on tumourigenesis that also have 553 
some function in the cell cycle (WEE1, MYC, AKT, CYCLINB1, P21, P27, K167) although 554 
many of these are also involved in apoptosis. Splitting up circadian genes’ role in apoptosis 555 
and proliferation may prove folly as the scope of circadian control is so vast and these pathways 556 
overlap to such a degree that it is likely that both are involved on some level. It is also important 557 
to note that a number of studies do see an increase in proliferation via MTT assay, colony 558 
formation assays or BrdU assays, but do not interrogate the exact mechanism for this increase, 559 
so we do not yet have an exhaustive list of what proteins and pathways are involved. 560 
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Clocks in the clinic - How to tell if Tumours Tick? 561 
Knowledge of the mechanisms underlying clock influence on human tumours is 562 
important, but equally important is the ability to translate this into a clinical setting. As 563 
previously mentioned, it is crucial to know the degree of circadian function of a tumour. 564 
Understanding the expression of oscillating genes is not as simple as looking for genes that are 565 
up or down regulated. Instead, we must ascertain the presence or absence of oscillation, the 566 
amplitude and phase of the oscillation, and the abundance of clock genes relative to the point 567 
of the circadian cycle. In addition, it is clear that clock gene expression differs based on tumour 568 
type, tissue type and the individual. In an age of personalised medicine, bespoke knowledge of 569 
the rhythmic function within individual tumours will be paramount. However, taking a biopsy 570 
on the hour every hour for 24 hours to assess rhythmicity is unlikely to be a popular option. To 571 
state simply, we require an innovative way to know if tumours tick in individuals and what that 572 
ticking looks like. 573 
Algorithms have been developed which aim to ascertain the biological time of single 574 
samples based on their transcriptome. Several supervised models have been trained using 575 
human circadian transcriptome datasets (Agostinelli et al., 2016, Hughey, 2017, Laing et al., 576 
2017, Braun et al., 2018, Wittenbrink et al., 2018). Circadian transcriptomics experiments in 577 
mice have demonstrated that expression of each clock gene is usually synchronised in phase 578 
across different tissues, but the magnitude of expression and amplitude of oscillation can differ 579 
(Zhang et al., 2014). For example, the algorithms ZeitZeiger, PSLR, BIO_CLOCK and 580 
BodyTime require that training and test datasets are tissue-matched, or even cell-matched 581 
(Wittenbrink et al., 2018). This means these time prediction algorithms are constrained to blood 582 
samples, for which training datasets around the clock are available. 583 
Alternatively, other mathematical methods have been suggested that do not rely on 584 
serial samples of individuals. CYCLOPS is a largely unsupervised method which requires 585 
reasonably large transcriptomic datasets (ideally >250 samples) composed of single samples 586 
from different individuals over the course of the day (Anafi et al., 2017). CYCLOPS-ordered 587 
hepatocellular carcinoma (HCC) tumour biopsies demonstrated population-wide oscillations 588 
in 8 of 9 core clock genes, but showed a reduction in amplitude of oscillation and magnitude 589 
of expression relative to CYCLOPS-ordered HCC tumour margins (Lamb et al., 2011, Anafi 590 
et al., 2017). Unfortunately, since rhythmic gene expression is estimated from the population, 591 
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CYCLOPS cannot estimate the variation in rhythmic gene expression between individuals 592 
(Anafi et al., 2017), which limits its clinical use. 593 
Another method that does not require tissue-matched, time-stamped training datasets, 594 
known as ΔCCD, is based on calculating the pairwise Spearman correlation of the expressions 595 
of all 12 core clock genes previously used to build ZeitZeiger (Hughey et al., 2016, Shilts et 596 
al., 2018). For each sample the resulting correlation matrix is then compared to a mouse healthy 597 
tissue reference matrix. Using this method, 20 tumour biopsy datasets differed from non-598 
tumour samples, indicating that core clock gene expression of the tumour samples was more 599 
different than clock gene expression of non-tumour samples, relative to the mouse reference. 600 
This suggests that core circadian gene expression is consistently disrupted in tumours over a 601 
population. Interestingly an unrelated algorithm, TimeTeller, trained using a circadian 602 
transcriptome data of healthy human oral mucosa biopsies, was used to predict the extent of 603 
molecular clock dysfunction in the biopsies of 226 breast cancer patients (Vlachou et al., 2019). 604 
Most importantly, clock dysfunction and overall survival correlated, suggesting a functional 605 
role for the tumour clock, which warrants further investigation. 606 
Mathematical models have been used to predict population level dysregulation of 607 
rhythmic gene expression from human tumour biopsies and have provided some insight into 608 
individual clock variation (Vlachou et al., 2019, Anafi et al., 2017, Shilts et al., 2018). Yet, 609 
there is poor correlation in the degree of clock gene dysregulation between different tumour 610 
types or even between cohorts of the same tumour type (Shilts et al., 2018, Ye et al., 2018). It 611 
is unclear whether this is a result of individual molecular clock difference, intertumoral 612 
difference, sampling-time difference, or perhaps another factor such as tumour grade. This 613 
demonstrates the importance of well-annotated publicly available datasets, ideally samples 614 
would be time-annotated. 615 
Conclusion and Future Directions 616 
In conclusion, there is a wealth of evidence at many levels which links the expression 617 
of circadian clock proteins to tumour biology and tumourigenesis. Though some of this 618 
evidence is limited, such as a lack of timing information for human biospecimen, it still seems 619 
overwhelmingly likely that there is a link between circadian clock gene expression and tumour 620 
development or progression. There is, however, not a very detailed mechanistic understanding 621 
if any given circadian clock gene is pro- or anti-tumourigenic, as the effects of gene’s products 622 
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appear cell-type specific. It is difficult to understand the cause of this cell specificity without 623 
greater knowledge of the underlying mechanisms of the role of circadian clock genes in 624 
tumourigenesis in these instances. Additionally, it is not known if the effect of circadian 625 
proteins on tumourigenesis is linked to their role in the clock or is a separate function regardless 626 
of oscillation. 627 
Deciphering the role of circadian clocks in human tumours requires not only an 628 
understanding of the degree of clock function in the tumour, but also an understanding of the 629 
degree of clock function in the healthy tissue of the host, ideally in the context of the 630 
individual’s overall behavioural rhythm. A number of ingenious mathematical models have 631 
been developed which have the potential to elucidate clock function from large transcriptomic 632 
datasets. However, the availability of timing information in the data, is important both for the 633 
training of these models and for their use in matching molecular clock status to clinical 634 
information. Important initiatives such as The Cancer Genome Atlas and the International 635 
Cancer Genome Consortium do not record time of sampling information, despite recording 636 
other important patient-specific metadata such as alcohol and smoking history. Time of 637 
sampling information would greatly improve the possible use of such datasets. An additional 638 
level of understanding about the patients' individual clocks could be gleaned from biopsies of 639 
healthy tissue similar to that of the tumour, this would be the gold standard for comparing the 640 
molecular clock of the healthy cells to those of the tumour. However, a more feasible and non-641 
invasive way of gaining this information may be to use a short chronotype questionnaire to 642 
determine the patient’s behavioural clock function  (Ghotbi et al., 2020). This review in part 643 
serves as an appeal to patient-facing clinicians involved in research. If circadian-cancer studies 644 
in humans are to substantially improve, then more annotation of samples with as much time 645 
information as possible is paramount. 646 
As for in vitro and in vivo modelling of the effects of clock genes on cancers, it will be 647 
important to strive for clinically relevant models. Effects of clock k/d in vitro do not always 648 
hold true in vivo. This is somewhat expected as, in vivo, tumour cells will be receiving 649 
synchronisation information from the SCN much like healthy cells. It is clear that the effects 650 
of circadian genes are highly cell type specific, and it is not yet clear what the reasons for this 651 
may be. The status of pathways such as p53 in the cells before the circadian aberration may 652 
play a key role. Testing circadian genes by a single knockdown in a single cell line gives 653 
interesting information but it is slow and cumbersome. A push towards screening more than 654 
one clock gene at a time and potentially testing the effects of the entire molecular clock at once 655 
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would allow a faster development of knowledge in this area. To ascertain if these effects are 656 
actually down to changes in the clock, or due to properties of clock genes which may have 657 
come uncoupled from their role in rhythms, it is useful to know the circadian health of a cell 658 
line before the modification and after. Some studies already test this but many do not. Better 659 
time matched human data and clinically relevant in vivo and in vitro analysis which takes into 660 
account the circadian system as a whole should go some way to allow us to pick apart the 661 
complex and varied roles that circadian genes appear to play in tumour biology.  662 
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Figure 1. A general overview of the molecular circadian clock. CLOCK/BMAL1 binds 1017 
to E-box elements in clock-controlled genes (CCGs). CCGs are varied, producing important 1018 
proteins such as p53, as well as circadian proteins which enter into feedback loops with 1019 
CLOCK/BMAL1. In the primary circadian loop PER and CRY proteins are translated and 1020 
accumulate in the cytoplasm. Here they form macromolecular cytoplasmic complexes with 1021 
other proteins including GAPVD1, who’s role in circadian biology remains largely elusive, 1022 
and CK1ε/δ. During this cytoplasmic phase a number of post-translational modifications occur 1023 
which modify the activity of the PERs and CRYs. PER2 phosphorylation is pictured as an 1024 
example, CK1ε/δ phosphorylates PER2 on either the FASP site or the degron site leading to 1025 
PER2 stabilisation or β-TrCP mediated degradation respectively. Stabilised PER2, along with 1026 
other members of the cytoplasmic circadian complex can be translocated to the nucleus. Here 1027 
a nuclear complex of PERs and CRYs can repress CLOCK/BMAL1 mediated transcriptional 1028 
activation and therefore, repress their own transcription. In the secondary loop RORs and REV-1029 
ERBs, who’s transcription is regulated by E-boxes, compete for access to ROR response 1030 
elements (RREs) with RORs promoting BMAL1 transcription and REV-ERBs repressing it. 1031 
Pictured here are two of the proposed sub loops. DEC1 and DEC2 repress PER1 transcription. 1032 
DBP mediates oscillatory transcription via D-box elements and is repressed by NFIL3, which 1033 
itself is transcribed via ROR activity at RREs. 1034 
 1035 
 1036 
Figure 2. An overview of the known data linking circadian genes to cancer which will 1037 
be discussed in this review. Green fill denotes an anti-tumourigenic effect of the gene, red fill 1038 
denotes a pro-tumourigenic effect of the gene, yellow fill denotes conflicting evidence with 1039 
some studies suggesting the gene to be anti- and others pro-tumourigenic. ┼ denotes a cell type 1040 
whos identity was potentially misattributed.  1041 


